NOVN), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=NOVN. The Company announced on October 18, 2017, that it has acquired exclusive worldwide intellectual property rights for certain oncovirus applications of the Company's nitric oxide-based products. An oncovirus is a cancer-causing virus. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) for due-diligence and potential coverage as the Company announced on October 17, 2017, its financial results for Q3 2017 which ended on September 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Brainstorm Cell Therapeutics when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on NOVN; also brushing on BCLI. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=NOVN

http://protraderdaily.com/optin/?symbol=BCLI

Benefits of the Agreement

The intellectual property rights enable Novan to expand its viral platform by exploring nitric oxide's antiviral activity against neoplasias and carcinomas caused by high-risk human papillomavirus (HPV).

The Company intends to focus HPV-related development on localized therapies to treat HPV-associated sexually transmitted infections.

The agreement also allows for potential future translations of nitric oxide as a treatment for rare and orphan diseases caused by other double-stranded DNA viruses.

Nitric Oxide Prohibits Replication of HPV Through a Mechanism

The Company has demonstrated Phase-2 statistically significant complete clearance rates of external genital warts caused by HPV with product candidate SB206. The preclinical data demonstrated the antiviral effects of Novan's nitric oxide-releasing drug candidates against the high-risk HPV-18 genotype and an inhibition of the E6 viral protein has been presented. E6 is observed to be a primary driver of HPV-related cancers and other abnormal growths.

Dr. Nathan Stasko, President and Chief Scientific Officer, stated that nitric oxide prohibits replication of HPV through a mechanism that potentially translates to numerous HPV subtypes.

Novan Initiated Clinical Development of Nitric Oxide Platform in Field of Immunology

Novan has also initiated clinical development of its nitric oxide platform in the field of immunology. The first patient has been enrolled and dosed in a Phase-1b clinical trial to evaluate topical product candidate SB414 cream for the treatment of psoriasis. The purpose of this trial is to evaluate safety and to assess target engagement through a reduction of key pro-inflammatory biomarkers like interleukin-17, or IL-17, before progressing to Phase-2 clinical trials.

Results of the trial are expected in Q2 2018. The Company will begin a Phase-1b trial with SB414 in adults with atopic dermatitis before the year-end and the top line results would be expected in Q3 2018.

What is Human Papillomavirus (HPV)?

HPV is a virus that is passed skin-to-skin through sexual intercourse or other forms of skin-to-skin contact of the genitals. There are over 100 subtypes of the virus, characterized as low-risk or high-risk based on their cancer-causing potential. Some kinds of HPV may cause problems like genital warts. Some kinds of HPV can also cause cancer of the cervix, vagina, vulva, or anus.

What is Psoriasis?

Psoriasis is a common, chronic, genetic, systemic inflammatory disease that is characterized by symptoms and signs such as elevated itchy plaques of raised red skin covered with thick silvery scales. It is usually found on the elbows, knees, and scalp but can often affect the legs, trunk, and nails. Psoriasis can cause tremendous discomfort and can interfere with normal daily activities, and there is no cure for it.

About Novan, Inc.

Founded in 2006, Novan, Inc. is a clinical-stage biotechnology company aiming to leverage nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The Company is headquartered in Morrisville, North Carolina.

Last Close Stock Review

Novan's share price finished yesterday's trading session at $5.32, advancing 4.11%. A total volume of 32.13 thousand shares have exchanged hands. The Company's stock price soared 31.36% in the last three months. The stock currently has a market cap of $80.86 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 478357

"/> Corporate News Blog – Novan Acquires Intellectual Property Rights for Treating Viral Malignancies with Nitric Oxide « MarketersMedia – Press Release Distribution Services – News Release Distribution Services

Corporate News Blog – Novan Acquires Intellectual Property Rights for Treating Viral Malignancies with Nitric Oxide

Research Desk Line-up: Brainstorm Cell Therapeutics Post Earnings Coverage

LONDON, UK / ACCESSWIRE / October 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Novan, Inc. (NASDAQ: NOVN), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=NOVN. The Company announced on October 18, 2017, that it has acquired exclusive worldwide intellectual property rights for certain oncovirus applications of the Company's nitric oxide-based products. An oncovirus is a cancer-causing virus. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) for due-diligence and potential coverage as the Company announced on October 17, 2017, its financial results for Q3 2017 which ended on September 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Brainstorm Cell Therapeutics when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on NOVN; also brushing on BCLI. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=NOVN

http://protraderdaily.com/optin/?symbol=BCLI

Benefits of the Agreement

The intellectual property rights enable Novan to expand its viral platform by exploring nitric oxide's antiviral activity against neoplasias and carcinomas caused by high-risk human papillomavirus (HPV).

The Company intends to focus HPV-related development on localized therapies to treat HPV-associated sexually transmitted infections.

The agreement also allows for potential future translations of nitric oxide as a treatment for rare and orphan diseases caused by other double-stranded DNA viruses.

Nitric Oxide Prohibits Replication of HPV Through a Mechanism

The Company has demonstrated Phase-2 statistically significant complete clearance rates of external genital warts caused by HPV with product candidate SB206. The preclinical data demonstrated the antiviral effects of Novan's nitric oxide-releasing drug candidates against the high-risk HPV-18 genotype and an inhibition of the E6 viral protein has been presented. E6 is observed to be a primary driver of HPV-related cancers and other abnormal growths.

Dr. Nathan Stasko, President and Chief Scientific Officer, stated that nitric oxide prohibits replication of HPV through a mechanism that potentially translates to numerous HPV subtypes.

Novan Initiated Clinical Development of Nitric Oxide Platform in Field of Immunology

Novan has also initiated clinical development of its nitric oxide platform in the field of immunology. The first patient has been enrolled and dosed in a Phase-1b clinical trial to evaluate topical product candidate SB414 cream for the treatment of psoriasis. The purpose of this trial is to evaluate safety and to assess target engagement through a reduction of key pro-inflammatory biomarkers like interleukin-17, or IL-17, before progressing to Phase-2 clinical trials.

Results of the trial are expected in Q2 2018. The Company will begin a Phase-1b trial with SB414 in adults with atopic dermatitis before the year-end and the top line results would be expected in Q3 2018.

What is Human Papillomavirus (HPV)?

HPV is a virus that is passed skin-to-skin through sexual intercourse or other forms of skin-to-skin contact of the genitals. There are over 100 subtypes of the virus, characterized as low-risk or high-risk based on their cancer-causing potential. Some kinds of HPV may cause problems like genital warts. Some kinds of HPV can also cause cancer of the cervix, vagina, vulva, or anus.

What is Psoriasis?

Psoriasis is a common, chronic, genetic, systemic inflammatory disease that is characterized by symptoms and signs such as elevated itchy plaques of raised red skin covered with thick silvery scales. It is usually found on the elbows, knees, and scalp but can often affect the legs, trunk, and nails. Psoriasis can cause tremendous discomfort and can interfere with normal daily activities, and there is no cure for it.

About Novan, Inc.

Founded in 2006, Novan, Inc. is a clinical-stage biotechnology company aiming to leverage nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The Company is headquartered in Morrisville, North Carolina.

Last Close Stock Review

Novan's share price finished yesterday's trading session at $5.32, advancing 4.11%. A total volume of 32.13 thousand shares have exchanged hands. The Company's stock price soared 31.36% in the last three months. The stock currently has a market cap of $80.86 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 478357

Research Desk Line-up: Brainstorm Cell Therapeutics Post Earnings Coverage

LONDON, UK / ACCESSWIRE / October 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Novan, Inc. (NASDAQ: NOVN), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=NOVN. The Company announced on October 18, 2017, that it has acquired exclusive worldwide intellectual property rights for certain oncovirus applications of the Company's nitric oxide-based products. An oncovirus is a cancer-causing virus. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) for due-diligence and potential coverage as the Company announced on October 17, 2017, its financial results for Q3 2017 which ended on September 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Brainstorm Cell Therapeutics when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on NOVN; also brushing on BCLI. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=NOVN

http://protraderdaily.com/optin/?symbol=BCLI

Benefits of the Agreement

The intellectual property rights enable Novan to expand its viral platform by exploring nitric oxide's antiviral activity against neoplasias and carcinomas caused by high-risk human papillomavirus (HPV).

The Company intends to focus HPV-related development on localized therapies to treat HPV-associated sexually transmitted infections.

The agreement also allows for potential future translations of nitric oxide as a treatment for rare and orphan diseases caused by other double-stranded DNA viruses.

Nitric Oxide Prohibits Replication of HPV Through a Mechanism

The Company has demonstrated Phase-2 statistically significant complete clearance rates of external genital warts caused by HPV with product candidate SB206. The preclinical data demonstrated the antiviral effects of Novan's nitric oxide-releasing drug candidates against the high-risk HPV-18 genotype and an inhibition of the E6 viral protein has been presented. E6 is observed to be a primary driver of HPV-related cancers and other abnormal growths.

Dr. Nathan Stasko, President and Chief Scientific Officer, stated that nitric oxide prohibits replication of HPV through a mechanism that potentially translates to numerous HPV subtypes.

Novan Initiated Clinical Development of Nitric Oxide Platform in Field of Immunology

Novan has also initiated clinical development of its nitric oxide platform in the field of immunology. The first patient has been enrolled and dosed in a Phase-1b clinical trial to evaluate topical product candidate SB414 cream for the treatment of psoriasis. The purpose of this trial is to evaluate safety and to assess target engagement through a reduction of key pro-inflammatory biomarkers like interleukin-17, or IL-17, before progressing to Phase-2 clinical trials.

Results of the trial are expected in Q2 2018. The Company will begin a Phase-1b trial with SB414 in adults with atopic dermatitis before the year-end and the top line results would be expected in Q3 2018.

What is Human Papillomavirus (HPV)?

HPV is a virus that is passed skin-to-skin through sexual intercourse or other forms of skin-to-skin contact of the genitals. There are over 100 subtypes of the virus, characterized as low-risk or high-risk based on their cancer-causing potential. Some kinds of HPV may cause problems like genital warts. Some kinds of HPV can also cause cancer of the cervix, vagina, vulva, or anus.

What is Psoriasis?

Psoriasis is a common, chronic, genetic, systemic inflammatory disease that is characterized by symptoms and signs such as elevated itchy plaques of raised red skin covered with thick silvery scales. It is usually found on the elbows, knees, and scalp but can often affect the legs, trunk, and nails. Psoriasis can cause tremendous discomfort and can interfere with normal daily activities, and there is no cure for it.

About Novan, Inc.

Founded in 2006, Novan, Inc. is a clinical-stage biotechnology company aiming to leverage nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The Company is headquartered in Morrisville, North Carolina.

Last Close Stock Review

Novan's share price finished yesterday's trading session at $5.32, advancing 4.11%. A total volume of 32.13 thousand shares have exchanged hands. The Company's stock price soared 31.36% in the last three months. The stock currently has a market cap of $80.86 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 478357

Source URL: https://marketersmedia.com/corporate-news-blog-novan-acquires-intellectual-property-rights-for-treating-viral-malignancies-with-nitric-oxide/253064

Source: AccessWire

Release ID: 253064


Latest News